Abstract || Annals of Clinical Case Reports

Major Scope

Cardiovascular Case Reports
Oncology Case Reports
Surgical Case Reports
Gastroenterological Case Reports
Neurological Case Reports
Dermatological Case Reports
Respiratory Case Reports
Obstetrics/Gynecology Case Reports
Nephrology Case Reports
Immunology Case Reports
Paediatric Case Reports
Orthopedics Case Reports
Dental Case Reports

Abstract

Citation: Ann Clin Case Rep. 2017;2(1):1251.DOI: 10.25107/2474-1655.1251

Metastatic Melanoma Responding to Combination Chemotherapy and Immunotherapy after Progression on Ipilimumab and Nivolumab Immunotherapy

Elen Vettus, David Draper and Michael A Davies

Department of Chemotherapy, Oncology and Haematology Clinic, North Estonia Medical Center, Estonia
Department of Medical Oncology, Tri Health Cancer Institute, USA
Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, USA

^*Correspondance to: Michael A Davies

PDF Full Text Case Report | Open Access

Abstract:

We report the case of a patient with stage IV M1c melanoma that developed symptomatic disease progression after treatment with combination immunotherapy (ipilimumab with nivolumab). The patient was subsequently treated with nab-paclitaxel chemotherapy and pembrolizumab and had a rapid and dramatic clinical response. The case illustrates that clinical responses are possible after progression on combination immunotherapy.

Keywords:

Metastatic melanoma; Nab-paclitaxel; Pembrolizumab; Ipilimumab; Nivolumab; Resistance

Cite the Article:

Vettus E, Draper D, Davies MA. Metastatic Melanoma Responding to Combination Chemotherapy and Immunotherapy after Progression on Ipilimumab and Nivolumab Immunotherapy. Ann Clin Case Rep. 2017; 2: 1251.